The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease
Open accessAbstract
Summary: Background: Preliminary data have suggested that interleukin‐2 receptor blockade with basiliximab may increase steroid sensitivity. We have previously reported a small case series demonstrating the potential of basiliximab as a novel agent for the treatment of steroid‐resistant ulcerative colitis. Aim: To report further experience of the efficacy and safety of treatment with the interleukin‐2 receptor blocking monoclonal antibody basiliximab, in addition to steroids, for the treatment of severe and moderate steroid‐resistant ulcerative colitis. Methods: Twenty patients were enrolled – 13 patients with moderate steroid‐resistant ulcerative colitis (Ulcerative Colitis Symptom Score: ≥6) and seven patients with severe steroid‐resistant ulcerative colitis. All were given a single dose of 40 mg basiliximab plus standard steroid therapy in an open‐label, uncontrolled trial. Primary end point was clinical remission within 8 weeks (Ulcerative Colitis Symptom Score: ≤2). Results: Within 8 weeks, 10 of 20 (50%) patients achieved clinical remission (seven of 13 moderate, and three of seven severe). At 24 weeks, 13 of 20 (65%) patients were in clinical remission. Five patients required colectomy (four severe, one moderate ulcerative colitis) and one required rescue ciclosporin (moderate ulcerative colitis). Two patients developed herpes zoster, but treatment was generally well tolerated. Conclusions: Basiliximab appears to promote prolonged remission after a single treatment. Taken in combination with previously reported data, basiliximab shows particular promise in moderate steroid‐resistant ulcerative colitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Role for STAT5 in the Pathogenesis of IL-2-Induced Glucocorticoid Resistance
Goleva, E., Kisich, K. O., & Leung, D. Y. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5934 · Cited by 113
Cited by
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Glucocorticoid resistance in inflammatory diseases
Barnes, P. J., & Adcock, I. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60326-3 · Cited by 983
Role of cytokines in inflammatory bowel disease
Sanchez-Muñoz, F., Dominguez-Lopez, A., & Yamamoto-Furusho, J. K. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.4280 · Cited by 699
European evidence-based Consensus on the management of ulcerative colitis: Current management
Travis, S. P. L., Stange, E. F., Lémann, M., Øresland, T., Bemelman, W. A., Chowers, Y., Colombel, J. F., D'Haens, G., Ghosh, S., Marteau, P., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.11.002 · Cited by 558
Metadata
- Authors
- CREED, T. J., PROBERT, C. S. J., NORMAN, M. N., MOORGHEN, M., SHEPHERD, N. A., HEARING, S. D., DAYAN, C. M., & THE BASBUC INVESTIGATORS
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-04-28
- Volume
- 23
- Issue
- 10
- Pages
- 1435-1442
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1985633590
- Cited by
- 101
- References
- 1
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease. https://app.cochat.ai/papers/10.1111/j.1365-2036.2006.02904.x
- The paper
- CREED, T. J., PROBERT, C. S. J., NORMAN, M. N., MOORGHEN, M., SHEPHERD, N. A., HEARING, S. D., DAYAN, C. M., & THE BASBUC INVESTIGATORS. (2006). Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2006.02904.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.